Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GMED's Cash to Debt is ranked higher than
88% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. GMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GMED' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6601
N/A
No Debt
Equity to Asset 0.86
GMED's Equity to Asset is ranked higher than
85% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. GMED: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
GMED' s Equity to Asset Range Over the Past 10 Years
Min: 0.83  Med: 0.86 Max: 0.86
Current: 0.86
0.83
0.86
F-Score: 5
Z-Score: 14.95
M-Score: -2.41
WACC vs ROIC
5.22%
27.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.61
GMED's Operating margin (%) is ranked higher than
97% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. GMED: 31.61 )
Ranked among companies with meaningful Operating margin (%) only.
GMED' s Operating margin (%) Range Over the Past 10 Years
Min: 23.4  Med: 29.56 Max: 31.61
Current: 31.61
23.4
31.61
Net-margin (%) 20.70
GMED's Net-margin (%) is ranked higher than
91% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.79 vs. GMED: 20.70 )
Ranked among companies with meaningful Net-margin (%) only.
GMED' s Net-margin (%) Range Over the Past 10 Years
Min: 15.79  Med: 19.02 Max: 20.7
Current: 20.7
15.79
20.7
ROE (%) 17.45
GMED's ROE (%) is ranked higher than
86% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. GMED: 17.45 )
Ranked among companies with meaningful ROE (%) only.
GMED' s ROE (%) Range Over the Past 10 Years
Min: 15.98  Med: 17.49 Max: 43.04
Current: 17.45
15.98
43.04
ROA (%) 14.66
GMED's ROA (%) is ranked higher than
93% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.56 vs. GMED: 14.66 )
Ranked among companies with meaningful ROA (%) only.
GMED' s ROA (%) Range Over the Past 10 Years
Min: 13.54  Med: 14.67 Max: 36.91
Current: 14.66
13.54
36.91
ROC (Joel Greenblatt) (%) 66.40
GMED's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. GMED: 66.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 59.22  Med: 69.97 Max: 139.86
Current: 66.4
59.22
139.86
Revenue Growth (3Y)(%) 10.60
GMED's Revenue Growth (3Y)(%) is ranked higher than
76% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. GMED: 10.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GMED' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 10.6  Med: 10.70 Max: 13.5
Current: 10.6
10.6
13.5
EBITDA Growth (3Y)(%) 12.30
GMED's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. GMED: 12.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GMED' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.5  Med: 9.90 Max: 12.3
Current: 12.3
4.5
12.3
EPS Growth (3Y)(%) 13.60
GMED's EPS Growth (3Y)(%) is ranked higher than
68% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. GMED: 13.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GMED' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.9  Med: 13.00 Max: 13.6
Current: 13.6
6.9
13.6
» GMED's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GMED Guru Trades in Q1 2015

Louis Moore Bacon 100,000 sh (New)
Steven Cohen 523,600 sh (-33.70%)
Joel Greenblatt 245,402 sh (-57.08%)
Paul Tudor Jones 19,032 sh (-57.70%)
Jim Simons 98,300 sh (-60.70%)
» More
Q2 2015

GMED Guru Trades in Q2 2015

Steven Cohen 659,525 sh (+25.96%)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Paul Tudor Jones 17,765 sh (-6.66%)
Joel Greenblatt 185,214 sh (-24.53%)
» More
Q3 2015

GMED Guru Trades in Q3 2015

Jim Simons 143,945 sh (New)
Paul Tudor Jones 54,995 sh (+209.57%)
Steven Cohen Sold Out
Joel Greenblatt 159,743 sh (-13.75%)
» More
Q4 2015

GMED Guru Trades in Q4 2015

John Paulson 132,300 sh (New)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones 29,768 sh (-45.87%)
» More
» Details

Insider Trades

Latest Guru Trades with GMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.17
GMED's P/E(ttm) is ranked higher than
62% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. GMED: 21.17 )
Ranked among companies with meaningful P/E(ttm) only.
GMED' s P/E(ttm) Range Over the Past 10 Years
Min: 12.95  Med: 24.21 Max: 35.54
Current: 21.17
12.95
35.54
Forward P/E 18.98
GMED's Forward P/E is ranked lower than
51% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 18.69 vs. GMED: 18.98 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.17
GMED's PE(NRI) is ranked higher than
62% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 26.85 vs. GMED: 21.17 )
Ranked among companies with meaningful PE(NRI) only.
GMED' s PE(NRI) Range Over the Past 10 Years
Min: 12.96  Med: 24.22 Max: 35.64
Current: 21.17
12.96
35.64
Price/Owner Earnings (ttm) 29.29
GMED's Price/Owner Earnings (ttm) is ranked higher than
52% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 30.19 vs. GMED: 29.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GMED' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 26.38  Med: 30.83 Max: 60.75
Current: 29.29
26.38
60.75
P/B 3.33
GMED's P/B is ranked lower than
57% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. GMED: 3.33 )
Ranked among companies with meaningful P/B only.
GMED' s P/B Range Over the Past 10 Years
Min: 2.45  Med: 3.77 Max: 4.94
Current: 3.33
2.45
4.94
P/S 4.40
GMED's P/S is ranked lower than
64% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. GMED: 4.40 )
Ranked among companies with meaningful P/S only.
GMED' s P/S Range Over the Past 10 Years
Min: 2.47  Med: 4.29 Max: 5.61
Current: 4.4
2.47
5.61
PFCF 33.66
GMED's PFCF is ranked lower than
55% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 31.36 vs. GMED: 33.66 )
Ranked among companies with meaningful PFCF only.
GMED' s PFCF Range Over the Past 10 Years
Min: 18.39  Med: 30.66 Max: 75.46
Current: 33.66
18.39
75.46
POCF 19.68
GMED's POCF is ranked higher than
52% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 19.89 vs. GMED: 19.68 )
Ranked among companies with meaningful POCF only.
GMED' s POCF Range Over the Past 10 Years
Min: 12.45  Med: 20.72 Max: 32.2
Current: 19.68
12.45
32.2
EV-to-EBIT 12.21
GMED's EV-to-EBIT is ranked higher than
77% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 20.77 vs. GMED: 12.21 )
Ranked among companies with meaningful EV-to-EBIT only.
GMED' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.5  Med: 14.40 Max: 21.3
Current: 12.21
6.5
21.3
EV-to-EBITDA 10.71
GMED's EV-to-EBITDA is ranked higher than
71% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 16.43 vs. GMED: 10.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
GMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 12.30 Max: 17.9
Current: 10.71
5.6
17.9
PEG 1.89
GMED's PEG is ranked higher than
69% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. GMED: 1.89 )
Ranked among companies with meaningful PEG only.
GMED' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 10104.9
Current: 1.89
0
10104.9
Current Ratio 6.59
GMED's Current Ratio is ranked higher than
86% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. GMED: 6.59 )
Ranked among companies with meaningful Current Ratio only.
GMED' s Current Ratio Range Over the Past 10 Years
Min: 5.26  Med: 6.59 Max: 9.11
Current: 6.59
5.26
9.11
Quick Ratio 5.32
GMED's Quick Ratio is ranked higher than
83% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. GMED: 5.32 )
Ranked among companies with meaningful Quick Ratio only.
GMED' s Quick Ratio Range Over the Past 10 Years
Min: 4.24  Med: 5.32 Max: 7.54
Current: 5.32
4.24
7.54
Days Inventory 275.89
GMED's Days Inventory is ranked lower than
80% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 134.42 vs. GMED: 275.89 )
Ranked among companies with meaningful Days Inventory only.
GMED' s Days Inventory Range Over the Past 10 Years
Min: 125.66  Med: 265.53 Max: 269.63
Current: 275.89
125.66
269.63
Days Sales Outstanding 52.05
GMED's Days Sales Outstanding is ranked higher than
75% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 70.19 vs. GMED: 52.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
GMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.59  Med: 52.05 Max: 58.04
Current: 52.05
50.59
58.04
Days Payable 43.90
GMED's Days Payable is ranked lower than
65% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 64.85 vs. GMED: 43.90 )
Ranked among companies with meaningful Days Payable only.
GMED' s Days Payable Range Over the Past 10 Years
Min: 28.24  Med: 43.90 Max: 52.36
Current: 43.9
28.24
52.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.69
GMED's Price/Net Cash is ranked higher than
51% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 14.74 vs. GMED: 14.69 )
Ranked among companies with meaningful Price/Net Cash only.
GMED' s Price/Net Cash Range Over the Past 10 Years
Min: 6.32  Med: 14.69 Max: 20.32
Current: 14.69
6.32
20.32
Price/Net Current Asset Value 5.59
GMED's Price/Net Current Asset Value is ranked higher than
54% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. GMED: 5.59 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GMED' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.2  Med: 6.03 Max: 6.39
Current: 5.59
3.2
6.39
Price/Tangible Book 4.04
GMED's Price/Tangible Book is ranked lower than
52% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 3.66 vs. GMED: 4.04 )
Ranked among companies with meaningful Price/Tangible Book only.
GMED' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.65  Med: 4.47 Max: 4.52
Current: 4.04
2.65
4.52
Price/Median PS Value 1.03
GMED's Price/Median PS Value is ranked higher than
51% of the 248 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. GMED: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
GMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 1.07 Max: 1.14
Current: 1.03
0.58
1.14
Price/Graham Number 1.95
GMED's Price/Graham Number is ranked higher than
53% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. GMED: 1.95 )
Ranked among companies with meaningful Price/Graham Number only.
GMED' s Price/Graham Number Range Over the Past 10 Years
Min: 1.24  Med: 2.20 Max: 2.34
Current: 1.95
1.24
2.34
Earnings Yield (Greenblatt) (%) 8.25
GMED's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. GMED: 8.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 6.90 Max: 15.4
Current: 8.25
4.7
15.4

More Statistics

Revenue(Mil) $545
EPS $ 1.18
Beta0.45
Short Percentage of Float18.77%
52-Week Range $20.48 - 28.99
Shares Outstanding(Mil)95.37

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 585 641 710
EPS($) 1.20 1.33 1.47
EPS without NRI($) 1.20 1.33 1.47

Business Description

Industry: Medical Devices » Medical Devices
Compare:SZSE:300003, NAS:ABMD, NZSE:FPH, OCSE:GN, OSTO:EKTA B, HKSE:01066 » details
Traded in other countries:GM0N.Germany,
Globus Medical Inc was incorporated in Delaware in March 3, 2003. The Company is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. It is currently focused on implants that promote healing in patients with spine disorders. All of its products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company's Innovative Fusion products address a spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. It currently offers over 120 products for the treatment of spine disorders. Products in Innovative Fusion includes: CREO, a convenient non-threaded locking cap design that eases building of thoracolumbar fixation constructs to readily adapt to the patient's anatomy and condition, for a range of clinical applications. XPAND, FORTIFY, FORTIFY-I corpectomy devices that incorporate smooth expansion capability, have a range of size options for optimal fit, and are manufactured from titanium or radiolucent polyetheretherketone. COALITION and INDEPENDENCE stand-alone interbody fusion devices, simplify the surgical technique by reducing steps and hardware while providing confident stabilization. Disruptive Technologies represent a shift in the treatment of spine disorders by allowing for novel surgical procedures, improvements to existing surgical procedures, and the treatment of spine disorders by new physician specialties, and surgical intervention earlier in the continuum of care. Products in Disruptive Technologies includes: MIS products which enable a surgeon to perform a procedure less invasively to minimize tissue disruption and maximize native anatomy, for patient recovery and fewer approach-related complications. For example, MARS 3V retractor system facilitates smaller incisions with the use of positionable radiolucent retractor blades to access the surgical site and to allow both direct and radiographic visualization. CALIBER, RISE and recently launched LATIS expandable interbody spacers are designed for reliable, minimally disruptive delivery through small MIS incisions with streamlined implants and instruments. REVOLVE pedicle screw system is designed for MIS screw and rod insertion through small incisions, and utilizes a convenient non-threaded locking cap design. TRANSITION, provide for stabilization that is less rigid than traditional pedicle screw systems for more natural load distribution to help promote fusion while maintaining stability. Other products included are SECURE-C, SECURE-CR, KINEX, MICROFUSE, SHIELD, AFFIRM, among others. Company's competitors include: Medtronic, the DePuy Synthes Companies, Stryker and NuVasive. Alphatec Spine, Orthofix International, Zimmer, LDR, among others. As of December 31, 2013, the Company owned 188 issued U.S. patents and had applicat

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK